首页> 美国卫生研究院文献>Osong Public Health and Research Perspectives >Ebola Hemorrhagic Fever and the Current State of Vaccine Development
【2h】

Ebola Hemorrhagic Fever and the Current State of Vaccine Development

机译:埃博拉出血热与疫苗发展现状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Current Ebola virus outbreak in West Africa already reached the total number of 1,323 including 729 deaths by July 31st. the fatality is around 55% in the southeastern area of Guinea, Sierra Leone, Liberia, and Nigeria. The number of patients with Ebola Hemorrhagic Fever (EHF) was continuously increasing even though the any effective therapeutics or vaccines has not been developed yet. The Ebola virus in Guinea showed 98% homology with Zaire Ebola Virus.Study of the pathogenesis of Ebola virus infection and assess of the various candidates of vaccine have been tried for a long time, especially in United States and some European countries. Even though the attenuated live vaccine and DNA vaccine containing Ebola viral genes were tested and showed efficacy in chimpanzees, those candidates still need clinical tests requiring much longer time than the preclinical development to be approved for the practical treatment.It can be expected to eradicate Ebola virus by a safe and efficient vaccine development similar to the case of smallpox virus which was extinguished from the world by the variola vaccine.
机译:截至7月31日,当前在西非的埃博拉病毒爆发总数已达到1,323例,其中729例死亡。在几内亚,塞拉利昂,利比里亚和尼日利亚的东南部,死亡人数约为55%。即使尚未开发出任何有效的疗法或疫苗,埃博拉出血热(EHF)的患者人数仍在不断增加。几内亚的埃博拉病毒与扎伊尔埃博拉病毒具有98%的同源性。长期以来一直在研究埃博拉病毒感染的发病机理并评估各种疫苗候选物,特别是在美国和一些欧洲国家。尽管已测试了包含埃博拉病毒基因的减毒活疫苗和DNA疫苗并在黑猩猩中显示出功效,但这些候选药物仍需要进行临床试验,所需的时间比批准临床治疗所需的临床前开发时间要长得多。通过安全,有效的疫苗开发来感染天花病毒,类似于天花疫苗已被天花疫苗扑灭。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号